| Autor: |
Wael Rumaneh, Taras I. Griadil, Ksenia I Chubirko, Ivan V Chopey, Mykhaylo M Hechko |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Wiadomości Lekarskie. 74:998-1002 |
| ISSN: |
0043-5147 |
| DOI: |
10.36740/wlek202104135 |
| Popis: |
OBJECTIVE The aim: To analyze and calculate CVR in patients with T2DM and concomitant obesity. PATIENTS AND METHODS Materials and methods: The selection of patients was carried out based on the Uzhhorod District Clinical Hospital, in the period from November 2016 to January 2020. All patients were divided into 3 groups: 1 (n=93) with T2DM and concomitant obesity, 2 (n=87) with T2DM, 3 (n=39) with obesity. The treatment period lasted 1 year and included dosed exercise for at least 30 minutes per day and dietary recommendations. Patients in groups 1 and 2 received metformin 850 mg twice daily in combination with dapagliflozin 10 mg once daily. CVR was determined at the time of enrollment and after 1 year of treatment using: American College of Cardiology / American Heart Association Guideline on the Assessment of Cardiovascular Risk (2013) (ASCVD Risk) and Framingham Risk Score (FRS). RESULTS Results: The data obtained as a result of the study revealed the highest CVR in patients of group 1, in contrast to group 2 and 3 (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
